Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in SyrSpendâ SF PH4 (dry).
Int J Antimicrob Agents
; 56(6): 106201, 2020 Dec.
Article
in English
| MEDLINE | ID: covidwho-974089
ABSTRACT
In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, hydroxychloroquine has been proposed as a potential agent to treat patients with COVID-19 (coronavirus disease 2019) caused by SARS-CoV-2 infection. Older adults are more susceptible to COVID-19 and some patients may require admission to the intensive care unit, where oral drug administration of solid forms may be compromised in many COVID-19 patients. However, a liquid formulation of hydroxychloroquine is not commercially available. This study describes how to prepare a 50 mg/mL hydroxychloroquine oral suspension using hydroxychloroquine sulfate powder and SyrSpendâ SF PH4 (dry) suspending vehicle. Moreover, a fully validated stability-indicating method has been developed to demonstrate the physicochemical stability of the compounded hydroxychloroquine oral suspension over 60 days under refrigeration (5 ± 3 °C). Finally, use of the proposed oral suspension provides a reliable solution to perform safe and accurate administration of hydroxychloroquine to patients with SARS-CoV-2 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Hydroxychloroquine
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Int J Antimicrob Agents
Year:
2020
Document Type:
Article
Affiliation country:
J.ijantimicag.2020.106201
Similar
MEDLINE
...
LILACS
LIS